Wockhardt Shares Gain Over 12%, Reaching 9-Month High Following Q4 Profit Turnaround

Wockhardt Shares Surge 12.55% to Reach 9-Month High

On December 1, Wockhardt, a major pharmaceutical and biotechnology company, witnessed a significant surge in its shares during the intraday session, reaching a 9-month high of ₹1,604 apiece. The company's turnaround performance in the quarter ended March was met with enthusiasm from investors, leading to a 12.55% increase in its shares.

The company reported a net profit of ₹164 crore in Q4FY26, a notable improvement from the net loss of ₹45 crore in the year-ago quarter. This turnaround was driven by strong growth in revenue, which jumped to ₹965 crore. The higher revenue was supported by a revival in the company's biotech and emerging markets businesses.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The company's biotech operations for the quarter came in at ₹252 crore, recording a growth of 126% over Q4FY25. On a full-year basis, biotech operations posted a 27% increase to ₹697 crore, driven by the emerging markets biotech segment, which grew 34% over FY25. The company expects its India biotech operations to continue growing at a double-digit pace and remain poised for healthy expansion in the coming years.

Wockhardt plans to launch insulin analogues over the next few years, representing a significant business opportunity. The company aims to target global diabetes healthcare needs while advancing its leadership position in diabetes care. For FY26, the company reported revenue growth of 11% over the previous year, with total revenue rising to ₹3,373 crore compared with ₹3,033 crore in FY25.

During FY26, the company recorded 15 filings, 13 approvals, and 23 launches in its international business. In biosimilars, it completed 11 filings and secured 16 approvals, while in the NCE segment, it made four filings and received one approval. The company also received approval for EMROK O and EMROK injection in Uganda.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Wockhardt's share price trend resumed its upward march in April, ending the month with a 19% gain. In the first two trading sessions of May, the shares have already advanced another 9%. Between April 2023 and June 2025, the stock witnessed a one-way rally, climbing from ₹154 apiece to ₹1,714, translating into a massive gain of over 1,000%. Along the way, it also touched a decade-high level of ₹1,868 apiece. In terms of yearly performance, the stock delivered a stellar 234% return in 2024, while in the following year it ended with a muted gain of 2.6%.